Age-related increase of plasma platelet-activating factor concentrations in Chinese

Clinica Chimica Acta

Volumn 337, Issue 1-2, 2003, Pages 157-162

  Zhang, Xiong ^a   Yuan, Cheng Lin ^a   Zhang, Heng Zhong ^a   Huang, Ru Xun ^b  

^a YANGZHOU UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Aging; Arteriosclerosis; Platelet activating factor; Radioimmunoassay

Indexed keywords

THROMBOCYTE ACTIVATING FACTOR;

ADULT; AGE; AGED; ARTICLE; CHINESE; CLINICAL EXAMINATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEVICE; EXTRACTION; FEMALE; GROUPS BY AGE; HEALTH SURVEY; HOSPITAL; HUMAN; MALE; MEDICAL EXAMINATION; PATIENT SELECTION; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL; PURIFICATION; RADIOIMMUNOASSAY; THIN LAYER CHROMATOGRAPHY;

EID: 0142227004     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cccn.2003.08.010     Document Type: Article

References (42)

1. Koltai M., Hosford D., Guinot P., Esanu A., Braquet P. Platelet-activating factor (PAF): a review of its effects, antagonists and possible future clinical implications (Part I). Drugs. 42:1991;9-29.
2. Prescott S.M., Zimmerman G.A., Stafforini D.M., McIntyre T.M. Platelet-activating factor and related lipid mediators. Annu. Rev. Biochem. 69:2000;419-445.
3. Benveniste J., Henson P.M., Cochrane C.G. Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils and a platelet-activating factor. J. Exp. Med. 136:1972;1356-1377.
4. Honda Z., Ishii S., Shimizu T. Platelet-activating factor receptor. J. Biochem. (Tokyo). 131:2002;773-779.
5. Tokumura A., Sumida T., Toujima M., Kogure K., Fukuzawa K. Platelet-activating factor (PAF)-like oxidized phospholipids: relevance to atherosclerosis. Biofactors. 13:2000;29-33.
6. Subbanagounder G., Leitinger N., Shih P.T., Faull K.F., Berliner J.A. Evidence that phospholipid oxidation products and/or platelet-activating factor play an important role in early atherogenesis: in vitro and in vivo inhibition by WEB 2086. Circ. Res. 85:1999;311-318.
7. Francescangeli E., Domanska-Janik K., Goracci G. Relative contribution of the de nove and remodelling pathways to the synthesis of platelet-activating factor in brain area and during ischemia. J. Lipid Mediators Cell Signal. 14:1996;89-98.
8. Bazan N.G. The neuromessenger platelet-activating factor in plasticity and neurodegeneration. Prog. Brain Res. 118:1998;281-291.
9. Loucks E.B., Godin D.V., Walley K.R., McManus B.M., Rahimian R., Granville D.J.et al. Role of platelet activating factor in cardiac dysfunction, apoptosis and nitric oxide synthase mRNA expression in the ischemic-reperfused rabbit heart. Can. J. Cardiol. 19:2003;267-274.
10. Nishida K., Markey S.P. Nicardipine and MK-801 attenuate PAF increases following cerebral ischemia-reperfusion in gerbils. Brain Res. 733:1996;203-210.
11. Aspey B.S., Alp M.S., Patel Y., Harrison M.J. Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study. Metab. Brain Dis. 12:1997;237-249.
12. Ko W., Lang D., Hawes A.S., Zelano J.A., Isom O.W., Krieger K.H. Platelet-activating factor antagonism attenuates platelet and neutrophil activation and reduces myocardial injury during coronary reperfusion. J. Surg. Res. 55:1993;504-515.
13. Qayumi A.K., English J.C., Godin D.V., Ansley D.M., Loucks E.B., Lee J.U.et al. The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury. Ann. Thorac .Surg. 65:1998;1690-1697.
14. Bielenberg G.W., Wagener D.G., Beck T. Infarct reduction by the platelet-activating factor antagonist apafant in rats. Stroke. 23:1992;98-103.
15. Sun D., Gilboe D.D. Effect of platelet-activating factor antagonist BN50739 and its diluents on mitochondrial respiration and membrane lipids during and following cerebral ischemia. J. Neurochem. 62:1994;1929-1938.
16. Satoh K., Imaizumi T., Yoshida H., Hiramoto M., Takamatsu S. Increased concentrations of blood platelet-activating factor (PAF) and PAF-like lipids in patients with ischemic stroke. Acta Neurol. Scand. 85:1992;122-127.
17. Zimmerman G.A., McIntyre T.M., Prescott S.M., Stafforini D.M. The platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit. Care Med. 30:2002;S294-S301.
18. Bazan N.G. Platelet-activating factor is both a modulator of synaptic function and a mediator of cerebral injury and inflammation. Adv. Neurol. 71:1996;475-482.
19. Park T.S., Gonzales E.R., Gidday J.M. Platelet-activating factor mediates ischemia-induced leukocyte-endothelial adherence in newborn pig brain. J. Cereb. Blood Flow Metab. 19:1999;417-424.
20. Smal M.A., Baldo B.A., McCaskill A. A specific, sensitive radioimmunoassay for platelet-activating factor (PAF). J. Immunol. Methods. 128:1990;183-188.
21. Sachais B.S. Platelet-endothelial interactions in atherosclerosis. Curr. Atheroscler. Rep. 3:2001;412-416.
22. Zimmerman G.A., McLntyre T.M., Prescott S.M. Adhesion and signaling in vascular cell-cell interactions. J. Clin. Invest. 97:1996;2784-2791.
23. Marathe G.K., Prescott S.M., Zimmerman G.A., McIntyre T.M. Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc. Med. 11:2001;139-142.
24. Frostegard J., Huang Y.H., Ronnelid J., Schafer-Elinder L. Platelet-activating factor and oxidized LDL induce immune activation by a common mechanism. Arterioscler. Thromb. Vasc. Biol. 17:1997;963-968.
25. Marathe G.K., Zimmerman G.A., Prescott S.M., McIntyre T.M. Activation of vascular cells by PAF-like lipids in oxidized LDL. Vasc. Pharmacol. 38:2002;193-200.
26. Kasapoglu M., Ozben T. Alterations of antioxidant enzymes and oxidative stress markers in aging. Exp. Gerontol. 36:2001;209-220.
27. Miquel J., Remirez-Bosca A., Diez A., Carrion-Gutierrez M.A., Diaz-Alperi J., Quintailla-Ripoll E.et al. Increase with age of serum lipid peroxides: implications for the prevention of atherosclerosis. Mech. Ageing Dev. 100:1998;17-24.
28. Grimble R.F. Inflammatory response in the elderly. Curr. Opin. Clin. Nutr. Metab. Care. 6:2003;21-29.
29. Bruunsgaard H., Pedersen M., Pedersen B.K. Aging and proinflammatory cytokines. Curr. Opin. Hematol. 8:2001;131-136.
30. Fiotti N., Giansante C., Ponte E., Delbello C., Calabrese S., Zacchi T. et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis. 145:1999;51-60.
31. Stafforini D.M., Tjoelker L.W., McCormick S.P., Vaitkus D., McIntyre T.M., Gray P.W.et al. Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J. Biol. Chem. 274:1999;7018-7024.
32. Forte T.M., Subbanagounder G., Berliner J.A., Blanche P.J., Clermont A.O., Jia Z.et al. Altered activities of anti-atherogenic enzymes LCAT, paraoxonase, and platelet-activating factor acetylhydrolase in atherosclerosis-susceptible mice. J. Lipid Res. 43:2002;477-485.
33. Mertens A., Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 15:2001;2073-2084.
34. Quarck R., De Geest B., Stengel D., Mertens A., Lox M., Theilmeier G.et al. Adenovirus mediated gene transfer of human platelet-activating factor acetylhydrolase prevents injury-induced neointima formation and reduces spontaneous atherosclerosis in apolipoprotein E-deficient mice. Circulation. 103:1999;2495-2500.
35. Unno N., Nakamura T., Kaneko H., Uchiyama T., Yamamoto N., Sugatani J.et al. Plasma platelet-activating factor acetylhydrolase deficiency is associated with atherosclerotic occlusive disease in Japan. J. Vasc. Surg. 32:2000;263-267.
36. Satoh K., Yoshida H., Imaizumi T., Takamatsu S., Mizuno S. Platelet-activating factor acetylhydrolase in plasma lipoprotein from patients with ischemic stroke. Stroke. 23:1992;1090-1092.
37. Yamada Y., Yoshida H., Ichihara S., Imaizumi T., Satoh K., Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 150:2000;209-216.
38. Kosaka T., Yamaguchi M., Miyanaga K., Mizuno K. Serum platelet-activating factor acetylhydrolase (PAF-AH) activity in more than 3000 healthy Japanese. Clin. Chim. Acta. 312:2001;179-183.
39. Milochevitch C., Khalil A. Study of the paraoxonase and platelet-activating factor acetylhydrolase activities with aging. Prostaglandins Leukot. Essent. Fatty Acids. 65:2001;241-246.
40. Benetos A., Waeber B., Izzo J., Mitchell G., Resnick L., Asmar R.et al. Influence of age, risk factors, and cardiovascular and renal disease on arterial stiffness: clinical applications. Am. J. Hypertens. 15:2002;1101-1108.
41. Brocheriou I., Stengel D., Mattsson-Hulten L., Stankova J., Rola-Pleszczynski M., Koskas F.et al. Expression of platelet-activating factor receptor in human carotid atherosclerotic plaques relevance to progression of atherosclerosis. Circulation. 102:2000;2569-2575.
42. Peplow P.V. Regulation of platelet-activating factor (PAF) activity in human diseases by phospholipase A2 inhibitors, PAF acetylhydrolases, PAF receptor antagonists and free radical scavengers. Prostaglandins Leukot. Essent. Fatty Acids. 61:1999;65-82.